Communiqués Solid Biosciences Inc.

Actions

SLDB

US83422E2046

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 22/09/2026			Varia. 5j.	Varia. 1 janv.
8,920 ^USD	+4,45%		+6,57%	+58,16%

16/09	L'approche de Solid Biosciences contre la dystrophie musculaire de Duchenne et le changement de cap de la FDA soutiennent le potentiel de hausse, selon RBC	MT
16/09	Solid Biosciences Inc. : RBC Capital Markets réitère son opinion positive sur le titre	ZM

Communiqués

02/09	Solid Biosciences to Participate at Upcoming Investor Conferences	AQ
06/08	Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates	AQ
01/06	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
01/06	Solid Biosciences to Participate at Upcoming Investor Conferences	AQ
12/05	Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates	AQ
07/05	Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy	AQ
01/05	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
30/04	Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy	AQ
28/04	Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy	AQ
07/04	Solid Biosciences to Participate at Upcoming Investor Conferences	AQ
19/03	Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates	AQ
11/03	Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial	AQ
06/03	Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference	AQ
06/03	Solid Biosciences Announces Oversubscribed $240 Million Private Placement	AQ
02/03	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
09/02	Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy	AQ
06/02	Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026	AQ
13/01	Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101	AQ
12/01	Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia	AQ
12/01	Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia	AQ
06/01	Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
05/01	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
16/12	Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services	AQ
08/12	Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum	AQ
01/12	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ